---
title: "Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292619451.md"
description: "Plus Therapeutics highlights updated NCCN CNS Cancers Guidelines, which emphasize cerebrospinal fluid (CSF) analysis for diagnosing and managing leptomeningeal metastases. The guidelines recommend regular CSF cytology follow-ups every 4 to 8 weeks during intrathecal therapy to monitor treatment efficacy and disease progression. This reinforces the clinical role of Plus Therapeutics' CNSide® in optimizing patient outcomes through comprehensive longitudinal monitoring."
datetime: "2026-07-14T11:31:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292619451.md)
  - [en](https://longbridge.com/en/news/292619451.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292619451.md)
generator: "portal-rs"
---

# Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Revised NCCN guidelines emphasize the importance of cerebrospinal fluid (CSF) analysis for diagnosing and managing leptomeningeal metastases. It recommends regular CSF cytology follow-ups every 4 to 8 weeks for patients undergoing intrathecal therapy. This approach aids in the ongoing monitoring of patients' conditions, ensuring comprehensive care. The updated guidelines reinforce the significance of CSF analysis in the clinical management of leptomeningeal metastases, underscoring the need for regular follow-ups to assess treatment efficacy and disease progression. These recommendations aim to optimize patient outcomes and enhance longitudinal monitoring of individuals with this condition.

### Related Stocks

- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)

## Related News & Research

- [Plus Therapeutics flags availability of CNS cancers guidelines update release](https://longbridge.com/en/news/292616746.md)
- [Cerenome Launches as an Integrated CNS Oncology Company | PSTV Stock News](https://longbridge.com/en/news/294514925.md)
- [BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?](https://longbridge.com/en/news/297786944.md)
- [BCAL Diagnostics Builds Early Cancer Detection Platform as Test Uptake Grows](https://longbridge.com/en/news/297849557.md)
- [06:05 ETKarmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer](https://longbridge.com/en/news/297497971.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**